Relevant Articles About Triple Negative Breast Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to assess serum fibronectin and gene polymorphisms as predictors of recurrence and treatment response in patients with NMIBC on BCG therapy. Researchers found elevated serum fibronectin predicts early recurrence in NMIBC but not BCG...
KEY TAKEAWAYS The study aimed to estimate the global prevalence of GIM through a systematic review and meta-analysis. The results showed the global prevalence of GIM is high, requiring further investigation and attention. Sara Soroorikia and the team aimed to...
KEY TAKEAWAYS The study aimed to investigate the role of CD247 and CD4 expression in TNBC prognosis. The results showed low CD247 and CD4 expression predicts poor outcomes in patients with TNBC. Ankit Pateriya and the team aimed to evaluate the prognostic...
The phase 1/2 trial aimed to investigate the safety, tolerability, and clinical activity of BDC-1001 + nivolumab in HER2+ advanced gastroesophageal cancers pts. …
The AVIATOR phase II trial aimed to evaluate the impact of incorporating avelumab, on the efficacy of standard chemo + H in refractory …
The NATALEE phase III trial aimed to evaluate iDFS benefit in stage II/III HR+/HER2− early BC patients by adding RIB to the adjuvant …
Background Chimeric antigen receptor (CAR)-T cells face many obstacles in solid tumor therapy, including heterogeneous antigen expression and inefficient T cell persistence. Guanylyl cyclase C (GUCY2C) has been identified as a suitable tumor antigen for targeted …
Background In addition to their established action of synthetic lethality in tumor cells, poly(ADP-ribose) polymerase inhibitors (PARPis) also orchestrate tumor immune microenvironment (TIME) that contributes to suppressing tumor growth. However, it remains not fully understood whether …
Background HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring a manageable safety profile. This phase I trial investigated the safety, pharmacokinetics, immunogenicity and preliminary efficacy …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …